N-Methyl-1-naphthalenemethylamine hydrochloride

We are N-Methyl-1-naphthalenemethylamine hydrochloride CAS:65473-13-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: N-Methyl-1-naphthalenemethylamine hydrochloride
CAS.NO:  65473-13-4
Synonyms:
N-methyl-1-naphthalen-1-ylmethanamine,hydrochloride
1-Naphthalenemethanamine, N-methyl-, hydrochloride (1:1)
N-Methyl-1-(naphthalen-1-yl)methanamine hydrochloride (1:1)
N-methyl-1-naphthalen-1-ylmethanamine,hydrochloride

Molecular Formula: C12H14ClN
Molecular Weight:  207.69900

Physical and Chemical Properties:
Density:1.05g/cm
Boiling point: 287.9ºC at 760 mmHg
Melting point: 191-193 °C(lit.)
Flash point:146.7ºC
Refractive index:/

Specification:
Appearance: white crystalline powder
Purity:≥98%
Water:≤0.5%
Single impurity:≤0.5%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Terbinafine  CAS: 91161-71-6
Intermediates of Terbinafine hydrochloride CAS:78628-80-5

Related News: In a stringent xenograft model of disseminated lymphoblastic leukemia, FT819 demonstrated enhanced tumor clearance and control of leukemia as compared to primary CAR19 T cells.334-61-2 It is understood that at present, the industry competition for global characteristic APIs has shown a development trend of vertical integration, and the number of mergers and acquisitions between pharmaceutical manufacturers and API manufacturers is increasing.352-93-2 From the perspective of the corresponding formulation manufacturer, the drug substance needs to meet the requirements of impurities and stability. The production base must pass the international quality system certifications such as cGMP and EuGMP. At the same time, the drug substance company must have sufficient capacity.4-(4-bromo-2-fluoroanilino)-6-methoxy-1H-quinazolin-7-one Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.